RU2006141834A - Суммарные экстракты из andrographis paniculata - Google Patents
Суммарные экстракты из andrographis paniculata Download PDFInfo
- Publication number
- RU2006141834A RU2006141834A RU2006141834/14A RU2006141834A RU2006141834A RU 2006141834 A RU2006141834 A RU 2006141834A RU 2006141834/14 A RU2006141834/14 A RU 2006141834/14A RU 2006141834 A RU2006141834 A RU 2006141834A RU 2006141834 A RU2006141834 A RU 2006141834A
- Authority
- RU
- Russia
- Prior art keywords
- deoxyandrographolide
- deoxy
- neoandrographolide
- extract contains
- andrografolida
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims 20
- 244000118350 Andrographis paniculata Species 0.000 title claims 4
- GVRNTWSGBWPJGS-DSJDWBEOSA-N 14-deoxyandrographolide Natural products O=C1C(CC[C@@H]2C(=C)CC[C@@H]3[C@@](CO)(C)[C@H](O)CC[C@]23C)=CCO1 GVRNTWSGBWPJGS-DSJDWBEOSA-N 0.000 claims 16
- GVRNTWSGBWPJGS-YSDSKTICSA-N 4-[2-[(1r,4as,5r,6r,8as)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]ethyl]-2h-furan-5-one Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)CC1=CCOC1=O GVRNTWSGBWPJGS-YSDSKTICSA-N 0.000 claims 16
- GVRNTWSGBWPJGS-UHFFFAOYSA-N deoxyandrographolide Natural products C=C1CCC2C(C)(CO)C(O)CCC2(C)C1CCC1=CCOC1=O GVRNTWSGBWPJGS-UHFFFAOYSA-N 0.000 claims 16
- YGCYRQKJYWQXHG-RDNQFMDVSA-N 4-[2-[(1r,4as,5r,8as)-5,8a-dimethyl-2-methylidene-5-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]ethyl]-2h-furan-5-one Chemical compound C([C@@]1(C)[C@H]2CCC(=C)[C@@H](CCC=3C(OCC=3)=O)[C@]2(C)CCC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YGCYRQKJYWQXHG-RDNQFMDVSA-N 0.000 claims 13
- MEEPUSVTMHGIPC-UHFFFAOYSA-N deoxyandrographiside Natural products OC1CCC2(C)C(CCC=3C(OCC=3)=O)C(=C)CCC2C1(C)COC1OC(CO)C(O)C(O)C1O MEEPUSVTMHGIPC-UHFFFAOYSA-N 0.000 claims 13
- BBGWVUQBIGGVLS-UHFFFAOYSA-N neoandrographolide Natural products CC1(COC2OC(CO)C(O)C(O)C2O)C(O)CCC3(C)C(CCC4=C(O)COC4=O)C(=C)CCC13 BBGWVUQBIGGVLS-UHFFFAOYSA-N 0.000 claims 13
- YGCYRQKJYWQXHG-UHFFFAOYSA-N neoandrographoside Natural products C1CCC2(C)C(CCC=3C(OCC=3)=O)C(=C)CCC2C1(C)COC1OC(CO)C(O)C(O)C1O YGCYRQKJYWQXHG-UHFFFAOYSA-N 0.000 claims 13
- XMJAJFVLHDIEHF-CRBRZBHVSA-N 14-Deoxy-11,12-didehydroandrographolide Chemical compound C(/[C@@H]1C(=C)CC[C@H]2[C@@]1(C)CC[C@@H](O)[C@]2(CO)C)=C\C1=CCOC1=O XMJAJFVLHDIEHF-CRBRZBHVSA-N 0.000 claims 11
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
Claims (21)
1. Способ ингибирования экспрессии TNF α у нуждающегося в этом субъекта, включающий введение субъекту эффективного количества экстракта из Andrographis paniculata.
2. Способ по п.1, где экстракт содержит андрографолид, 14-дезоксиандрографолид, 14-дезокси-11,12-дегидроандрографолид и неоандрографолид.
3. Способ по п.2, где экстракт содержит 2-20 мас.% андрографолида, 1-6 мас.% 14-дезоксиандрографолида, 1-12 мас.% 14-дезокси-11,12-дегидроандрографолида и 1-5 мас.% неоандрографолида.
4. Способ по п.3, где экстракт содержит 3-8 мас.% андрографолида, 3-5 мас.% 14-дезоксиандрографолида, 7-9 мас.% 14-дезокси-11,12-дегидроандрографолида и 2-4 мас.% неоандрографолида.
5. Способ по п.4, где экстракт содержит 4,2 мас.% андрографолида, 4,4 мас.% 14-дезоксиандрографолида, 8 мас.% 14-дезокси-11,12-дегидроандрографолида и 2,1 мас.% неоандрографолида.
6. Способ ингибирования экспрессии IL-1β у нуждающегося в этом субъекта, включающий введение субъекту эффективного количества экстракта из Andrographis paniculata.
7. Способ по п.6, где экстракт содержит андрографолид, 14-дезоксиандрографолид, 14-дезокси-11,12-дегидроандрографолид и неоандрографолид.
8. Способ по п.7, где экстракт содержит 2-20 мас.% андрографолида, 1-6 мас.% 14-дезоксиандрографолида, 1-12 мас.% 14-дезокси-11,12-дегидроандрографолида и 1-5 мас.% неоандрографолида.
9. Способ по п.8, где экстракт содержит 3-8 мас.% андрографолида, 3-5 мас.% 14-дезоксиандрографолида, 7-9 мас.% 14-дезокси-11,12-дегидроандрографолида и 2-4 мас.% неоандрографолида.
10. Способ по п.9, где экстракт содержит 4,2 мас.% андрографолида, 4,4 мас.% 14-дезоксиандрографолида, 8 мас.% 14-дезокси-11,12-дегидроандрографолида и 2,1 мас.% неоандрографолида.
11. Способ лечения воспалительного заболевания кишечника у нуждающегося в этом субъекта, включающий введение субъекту эффективного количества экстракта из Andrographis paniculata.
12. Способ по п.11, где экстракт содержит андрографолид, 14-дезоксиандрографолид, 14-дезокси-11,12-дегидроандрографолид и неоандрографолид.
13. Способ по п.12, где экстракт содержит 2-20 мас.% андрографолида, 1-6 мас.% 14-дезоксиандрографолида, 1-12 мас.% 14-дезокси-11,12-дегидроандрографолида и 1-5 мас.% неоандрографолида.
14. Способ по п.13, где экстракт содержит 3-8 мас.% андрографолида, 3-5 мас.% 14-дезоксиандрографолида, 7-9 мас.% 14-дезокси-11,12-дегидроандрографолида и 2-4 мас.% неоандрографолида.
15. Способ по п.14, где экстракт содержит 4,2 мас.% андрографолида, 4,4 мас.% 14-дезоксиандрографолида, 8 мас.% 14-дезокси-11,12-дегидроандрографолида и 2,1 мас.% неоандрографолида.
16. Способ по п.11, где воспалительным заболеванием кишечника является болезнь Крона.
17. Способ по п.16, где экстракт содержит андрографолид, 14-дезоксиандрографолид, 14-дезокси-11,12-дегидроандрографолид и неоандрографолид.
18. Способ по п.17, где экстракт содержит 2-20 мас.% андрографолида, 1-6 мас.% 14-дезоксиандрографолида, 1-12 мас.% 14-дезокси-11,12-дегидроандрографолида и 1-5 мас.% неоандрографолида.
19. Способ по п.11, где воспалительным заболеванием кишечника является язвенный колит.
20. Способ по п.19, где экстракт содержит андрографолид, 14-дезоксиандрографолид, 14-дезокси-11,12-дегидроандрографолид и неоандрографолид.
21. Способ по п.20, где экстракт содержит 2-20 мас.% андрографолида, 1-6 мас.% 14-дезоксиандрографолида, 1-12 мас.% 14-дезокси-11,12-дегидроандрографолида и 1-5 мас.% неоандрографолида.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56647704P | 2004-04-28 | 2004-04-28 | |
| US60/566,477 | 2004-04-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006141834A true RU2006141834A (ru) | 2008-06-10 |
| RU2383353C2 RU2383353C2 (ru) | 2010-03-10 |
Family
ID=35242143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006141834/14A RU2383353C2 (ru) | 2004-04-28 | 2005-04-26 | Суммарные экстракты из andrographis paniculata |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US7341748B2 (ru) |
| EP (1) | EP1747008B1 (ru) |
| JP (1) | JP5221128B2 (ru) |
| KR (3) | KR101531116B1 (ru) |
| AU (1) | AU2005237550B2 (ru) |
| CA (1) | CA2564637C (ru) |
| DK (1) | DK1747008T3 (ru) |
| ES (1) | ES2534594T3 (ru) |
| HU (1) | HUE025117T2 (ru) |
| PL (1) | PL1747008T3 (ru) |
| PT (1) | PT1747008E (ru) |
| RU (1) | RU2383353C2 (ru) |
| TW (1) | TWI373340B (ru) |
| WO (1) | WO2005104722A2 (ru) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070049103A (ko) * | 2004-03-11 | 2007-05-10 | 허치슨 메디파르마 리미티드 | ＴＮＦα 및 ＩＬ-1β 발현 억제제로서 안드로그라폴라이드및 유사체 |
| KR101531116B1 (ko) | 2004-04-28 | 2015-06-23 | 누트리션 사이언스 파트너스 리미티드 | 천심련으로부터의 조추출물 |
| JP2007176934A (ja) * | 2005-11-30 | 2007-07-12 | Kose Corp | 血小板活性化因子アセチルヒドロラーゼ機能調整剤 |
| US20070202164A1 (en) * | 2006-02-28 | 2007-08-30 | Hutchison Medipharma Enterprises Limited | Andrographis Extract Formulations |
| EP1882473A1 (en) * | 2006-07-28 | 2008-01-30 | Indena S.P.A. | Use of anthocyanosides to prepare formulations for the treatment of mucositis induced by antitumoral drugs |
| US20090117209A1 (en) * | 2007-11-02 | 2009-05-07 | Hutchison Medipharma Enterprises Limited | Andrographis paniculata extract |
| WO2010110748A1 (en) * | 2009-03-24 | 2010-09-30 | National University Of Singapore | Use of andrographolide compounds for treating inflammation and airway disorders |
| MD480Z5 (ru) * | 2011-07-07 | 2012-09-30 | Эльвира АНДОН | Метод лечения острого язвенного неспецифического колита |
| CN102702147B (zh) * | 2012-06-18 | 2016-06-08 | 辽宁利锋科技开发有限公司 | 穿心莲内酯类似物及其治疗的应用 |
| CN103145660B (zh) * | 2013-03-25 | 2014-09-17 | 成都天台山制药有限公司 | 穿心莲内酯及其制备方法 |
| CN103145661B (zh) * | 2013-03-25 | 2014-06-18 | 成都天台山制药有限公司 | 穿心莲内酯的新晶型 |
| CN103223028A (zh) * | 2013-03-27 | 2013-07-31 | 张宗升 | 中药提取物 |
| CN103766901A (zh) * | 2014-01-08 | 2014-05-07 | 浙江大学 | 一种穿心莲丙素在制备减肥食品或药品中的应用 |
| JP6386761B2 (ja) * | 2014-03-19 | 2018-09-05 | 花王株式会社 | インボルクリン発現抑制剤 |
| MY176459A (en) | 2016-05-23 | 2020-08-10 | Univ Putra Malaysia | Extract of andrographis paniculata for cognitive enhancement |
| WO2018081959A1 (en) * | 2016-11-02 | 2018-05-11 | Nutrition Science Partners Limited | Extracts of andrographis paniculata, methods for preparation and use thereof |
| CN107349253A (zh) * | 2017-06-23 | 2017-11-17 | 苏州凌科特新材料有限公司 | 无刺激医用消毒液及其制备方法 |
| WO2022058422A1 (en) * | 2020-09-17 | 2022-03-24 | Dsm Ip Assets B.V. | Use of andrographis paniculata extract to protect against air pollution related diseases |
| WO2024092327A1 (pt) * | 2022-10-31 | 2024-05-10 | Mey, Angelica Machado | Composição para obtenção de bioativo natural para terapias oncológicas |
| KR102713383B1 (ko) * | 2023-09-04 | 2024-10-04 | 김현주 | 인간을 제외한 동물의 면역력 증진을 위한 조성물 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1012941B (zh) | 1989-07-29 | 1991-06-26 | 郭如明 | 穿心莲碱水法新工艺 |
| WO1996017605A1 (en) * | 1994-12-06 | 1996-06-13 | Paracelsian, Inc. | Use of andrographolide compounds to treat or prevent pathogenicity of diseases |
| US20030059471A1 (en) | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
| JP4124573B2 (ja) * | 1998-03-17 | 2008-07-23 | 中外製薬株式会社 | Ｉｌ−６アンタゴニストを有効成分として含有する炎症性腸疾患の予防又は治療剤 |
| JP2000034233A (ja) * | 1998-07-15 | 2000-02-02 | Sumitomo Forestry Co Ltd | 一酸化窒素産生抑制剤 |
| JP2001058969A (ja) * | 1999-08-20 | 2001-03-06 | Nettairin Saisei Gijutsu Kenkyu Kumiai | 一酸化窒素産生抑制剤 |
| DE60119534T2 (de) | 2000-07-28 | 2007-05-10 | Immupharm Aps | Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen |
| US6629835B2 (en) | 2000-08-01 | 2003-10-07 | Metaproteomics, Llc | Combinations of diterpene triepoxide lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2 |
| US6358526B1 (en) | 2000-08-16 | 2002-03-19 | Rexall Sundown | Method of making tablets and tablet compositions produced therefrom |
| US7270835B2 (en) | 2001-06-20 | 2007-09-18 | Metaproteomics, Llc | Compositions that treat or inhibit pathological conditions associated with inflammatory response |
| US20030101076A1 (en) | 2001-10-02 | 2003-05-29 | Zaleski John R. | System for supporting clinical decision making through the modeling of acquired patient medical information |
| US6753017B2 (en) | 2001-11-07 | 2004-06-22 | Jrs Pharma Lp | Process for preparing dry extracts |
| JP2003171301A (ja) | 2001-11-09 | 2003-06-20 | Mahidol Univ | 歯周炎治療における補助剤としてのカルメグゲル |
| JP4669920B2 (ja) | 2002-08-21 | 2011-04-13 | 沖縄県 | 血糖上昇抑制且つ血圧上昇抑制作用を有する機能性素材 |
| CN1488376A (zh) | 2003-05-09 | 2004-04-14 | 江西诚志信丰药业有限责任公司 | 一种治疗肠道疾病及鼻窦炎的药物胶囊及其制备方法 |
| CN1626076B (zh) | 2003-12-11 | 2010-10-06 | 天津天士力制药股份有限公司 | 一种穿心莲内酯滴丸及其制备方法 |
| KR101065608B1 (ko) | 2003-12-29 | 2011-09-19 | 주식회사 엘지생활건강 | 안드로그라폴라이드 또는 안드로그라폴라이드를유효성분으로 함유하는 천심련 추출물을 포함하는가려움증 억제 또는 완화 조성물 |
| KR20070049103A (ko) | 2004-03-11 | 2007-05-10 | 허치슨 메디파르마 리미티드 | ＴＮＦα 및 ＩＬ-1β 발현 억제제로서 안드로그라폴라이드및 유사체 |
| KR101531116B1 (ko) | 2004-04-28 | 2015-06-23 | 누트리션 사이언스 파트너스 리미티드 | 천심련으로부터의 조추출물 |
| US20070218114A1 (en) | 2004-06-12 | 2007-09-20 | Passionfor Life Healthcare Limited | Soluble Strip for Oral or Topical Administration |
| CN1628764A (zh) | 2004-08-19 | 2005-06-22 | 贵阳云岩西创药物科技开发有限公司 | 穿心莲制剂及其制备方法 |
| US20070202164A1 (en) | 2006-02-28 | 2007-08-30 | Hutchison Medipharma Enterprises Limited | Andrographis Extract Formulations |
| US20090117209A1 (en) | 2007-11-02 | 2009-05-07 | Hutchison Medipharma Enterprises Limited | Andrographis paniculata extract |
-
2005
- 2005-04-26 KR KR1020137001151A patent/KR101531116B1/ko not_active Expired - Fee Related
- 2005-04-26 ES ES05742174.5T patent/ES2534594T3/es not_active Expired - Lifetime
- 2005-04-26 RU RU2006141834/14A patent/RU2383353C2/ru active
- 2005-04-26 HU HUE05742174A patent/HUE025117T2/en unknown
- 2005-04-26 AU AU2005237550A patent/AU2005237550B2/en not_active Ceased
- 2005-04-26 EP EP05742174.5A patent/EP1747008B1/en not_active Expired - Lifetime
- 2005-04-26 CA CA2564637A patent/CA2564637C/en not_active Expired - Lifetime
- 2005-04-26 KR KR1020157010077A patent/KR101536892B1/ko not_active Expired - Fee Related
- 2005-04-26 JP JP2007510891A patent/JP5221128B2/ja not_active Expired - Fee Related
- 2005-04-26 DK DK05742174T patent/DK1747008T3/en active
- 2005-04-26 PT PT05742174T patent/PT1747008E/pt unknown
- 2005-04-26 PL PL05742174T patent/PL1747008T3/pl unknown
- 2005-04-26 KR KR1020067025043A patent/KR101534844B1/ko not_active Expired - Fee Related
- 2005-04-26 WO PCT/US2005/014288 patent/WO2005104722A2/en not_active Ceased
- 2005-04-27 US US11/116,678 patent/US7341748B2/en not_active Ceased
- 2005-04-27 TW TW094113415A patent/TWI373340B/zh not_active IP Right Cessation
-
2010
- 2010-03-04 US US12/717,260 patent/USRE42718E1/en not_active Expired - Lifetime
-
2011
- 2011-07-22 US US13/189,444 patent/USRE43423E1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| USRE43423E1 (en) | 2012-05-29 |
| EP1747008B1 (en) | 2015-01-14 |
| CA2564637A1 (en) | 2005-11-10 |
| TW200538144A (en) | 2005-12-01 |
| HUE025117T2 (en) | 2016-02-29 |
| AU2005237550A1 (en) | 2005-11-10 |
| EP1747008A2 (en) | 2007-01-31 |
| RU2383353C2 (ru) | 2010-03-10 |
| US20060246156A1 (en) | 2006-11-02 |
| KR20070033982A (ko) | 2007-03-27 |
| KR20130012979A (ko) | 2013-02-05 |
| KR101536892B1 (ko) | 2015-07-14 |
| DK1747008T3 (en) | 2015-03-30 |
| ES2534594T3 (es) | 2015-04-24 |
| WO2005104722A2 (en) | 2005-11-10 |
| US7341748B2 (en) | 2008-03-11 |
| JP2007535542A (ja) | 2007-12-06 |
| CA2564637C (en) | 2013-09-10 |
| WO2005104722A3 (en) | 2006-03-02 |
| EP1747008A4 (en) | 2009-04-22 |
| KR101534844B1 (ko) | 2015-07-07 |
| AU2005237550B2 (en) | 2010-09-23 |
| KR101531116B1 (ko) | 2015-06-23 |
| PL1747008T3 (pl) | 2015-10-30 |
| PT1747008E (pt) | 2015-03-31 |
| JP5221128B2 (ja) | 2013-06-26 |
| TWI373340B (en) | 2012-10-01 |
| KR20150047645A (ko) | 2015-05-04 |
| USRE42718E1 (en) | 2011-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006141834A (ru) | Суммарные экстракты из andrographis paniculata | |
| Yaeesh et al. | Antihepatotoxic activity of Saussurea lappa extract on D‐galactosamine and lipopolysaccharide‐induced hepatitis in mice | |
| CN103961558A (zh) | 一种解酒护肝的铁皮石斛速溶颗粒 | |
| CN101675781A (zh) | 一种生姜腌制而成的咸味小菜 | |
| Abbasi et al. | Preliminary phytochemical analysis and in vivo evaluation of antipyretic effects of hydro-methanolic extract of Cleome scaposa leaves | |
| CN103798451A (zh) | 一种清热泻火凉茶 | |
| CN108210659A (zh) | 一种防流感香囊及其制作方法 | |
| González et al. | Plant-based remedies for wolf bites and rituals against wolves in the Iberian Peninsula: Therapeutic opportunities and cultural values for the conservation of biocultural diversity | |
| NO20016211D0 (no) | Forhindring av diabetes type 1 og andre ikke-polio enterovirus-sykdommer | |
| JP2005501923A5 (ru) | ||
| CN105878865A (zh) | 一种治疗湿疹的中药 | |
| CN105079277A (zh) | 一种威灵仙酒及其制备方法 | |
| CN103947799B (zh) | 五草保健茶 | |
| CN103463385A (zh) | 一种治疗遮目鱼细菌病的药物组合物及其制备方法 | |
| CN103341132B (zh) | 一种抗疟药胶囊及其制备方法 | |
| CN1633984A (zh) | 即冲型艾洗浴剂 | |
| CN106901418A (zh) | 一种治疗膝盖痛的医疗器械 | |
| CN106538854A (zh) | 一种用于湿热内蕴型羊布氏杆菌的饲料添加剂 | |
| CN107496760A (zh) | 一种治疗皮炎湿疹的内服药物及其制备方法 | |
| CN106389729A (zh) | 一种用于羊破伤病的饲料添加剂 | |
| Dempsey et al. | Excerpt from'Mary Medusa' | |
| Rohrer | Mongolian Death Worm | |
| CN103285317A (zh) | 一种消肿止痛药膏 | |
| CN104491491A (zh) | 一种预防破伤风的中药喷雾剂及其制备方法 | |
| CN106729474A (zh) | 一种用于治疗外感风寒里热的中药 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20130902 |